Diagnostic et traitement de la dépression chez les patients souffrant de cancer

Thirty percent of cancer patients experience depression during the course of their illness. Depression may occur at several key-moments: after diagnosis, a relapse, in the context of treatment failure. Depression is correlated with biological factors due to illness itself and its treatments, but also with inappropriate coping strategies. Diagnosis of depression is not straightforward in cancer patients. Its phenomenology is specific. Moreover, patients as well as clinicians may be reluctant to address the problem of psychological well-being. The treatment of depression has proven to increase quality of life as well as satisfaction with treatments and compliance. Antidepressants are the first line treatment. Psychotherapy and several psychological interventions are considered to be a valid alternative. In most severe cases a combined treatment is mandatory. [References: 6]]]> fre oai:serval.unil.ch:BIB_76098875844A 2022-05-07T01:20:40Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_76098875844A Equity access and economic evaluation in rare diseases: the impact of orphan drug legislation on health policy and patient care http://www.ingentaconnect.com/content/adis/pdr/2003/00000001/00000003/art00001 Bosanquet, Nick Domenighetti, Gianfranco Beresniak, Ariel Auray, Jean-Paul Crivelli, Luca Richard, L. Howard, P. info:eu-repo/semantics/article article 2003 Pharmaceutical Development and Regulation, vol. 1, no. 3, pp. 151-157 info:eu-repo/semantics/altIdentifier/pissn/1175-9046 Rare Diseases ; Orphan Drug Production ; Health Policy eng oai:serval.unil.ch:BIB_7609B9070C7F 2022-05-07T01:20:40Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_7609B9070C7F Minocycline-induced activation of tetracycline-responsive promoter. info:doi:10.1016/j.neulet.2003.08.067 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.neulet.2003.08.067 info:eu-repo/semantics/altIdentifier/pmid/14625008 Chtarto, A. Tenenbaum, L. Velu, T. Brotchi, J. Levivier, M. Blum, D. info:eu-repo/semantics/article article 2003 Neuroscience Letters, vol. 352, no. 3, pp. 155-158 info:eu-repo/semantics/altIdentifier/pissn/0304-3940 urn:issn:0304-3940 <![CDATA[Minocycline has been suggested to be an anti-apoptotic compound and an anti-inflammatory agent in various models of neurodegeneration. In the present study, using a stable cell line expressing green fluorescent protein under the control of a tetracycline-responsive promoter, we demonstrate that minocycline is able to promote tetracycline-controlled gene expression although it needs longer time and higher concentration to reach the effect obtained with the classical inducer doxycycline. Furthermore, the extinction of the system after antibiotics removal is faster when using minocycline. Interestingly, minocycline displays lower cytotoxicity than doxycycline. It is thus tempting to speculate that combining the intrinsic neuroprotective activity of minocycline with its ability to induce tetracycline-regulatable promoters would be greatly beneficial for neuroprotective/neurorestaurative gene therapy

A quality metric for homology modeling: the H-factor

<p>Abstract</p> <p>Background</p> <p>The analysis of protein structures provides fundamental insight into most biochemical functions and consequently into the cause and possible treatment of diseases. As the structures of most known proteins cannot be solved experimentally for technical or sometimes simply for time constraints, <it>in silico </it>protein structure prediction is expected to step in and generate a more complete picture of the protein structure universe. Molecular modeling of protein structures is a fast growing field and tremendous works have been done since the publication of the very first model. The growth of modeling techniques and more specifically of those that rely on the existing experimental knowledge of protein structures is intimately linked to the developments of high resolution, experimental techniques such as NMR, X-ray crystallography and electron microscopy. This strong connection between experimental and <it>in silico </it>methods is however not devoid of criticisms and concerns among modelers as well as among experimentalists.</p> <p>Results</p> <p>In this paper, we focus on homology-modeling and more specifically, we review how it is perceived by the structural biology community and what can be done to impress on the experimentalists that it can be a valuable resource to them. We review the common practices and provide a set of guidelines for building better models. For that purpose, we introduce the H-factor, a new indicator for assessing the quality of homology models, mimicking the R-factor in X-ray crystallography. The methods for computing the H-factor is fully described and validated on a series of test cases.</p> <p>Conclusions</p> <p>We have developed a web service for computing the H-factor for models of a protein structure. This service is freely accessible at <url>http://koehllab.genomecenter.ucdavis.edu/toolkit/h-factor</url>.</p

La mort, un commencement

La souffrance des personnes en fin de vie, et de leur famille, n’est pas modulée seulement par la perspective qu’ils ont de la mort, plutôt difficile à imaginer, mais aussi par le bilan qu’ils font de leur « histoire de vie ». Ce bilan s’élabore selon une représentation complexe de la situation (à la fois individuelle, familiale et sociale), et qui est en particulier fortement tributaire des normes, des règles et des loyautés sous-tendant l’éthique de la famille de celui qui va mourir. Suivant les circonstances et en fonction de la manière dont, dès le début, le patient et ses proches se sont aménagés par rapport aux limites, il faudra reprendre avec eux les différentes étapes du processus de deuil ( « mourning » ) qui est à l’oeuvre tout au long de la vie, et plus précisément aux moments charnières ou de crise.The suffering of people at the end of their lives, and that of their families, is not only modulated by their perspective on death, which is rather difficult to imagine, but also by the evaluation they make of their "life history." This assessment is drawn up according to a complex representation of the situation (simultaneously individual, familial and social), which is, in particular, strongly dependent on the norms, rules and loyalties underlying the family ethic for those about to die. Based on the circumstances and according to the manner in which the patient and those close to him have equipped themselves, from the beginning, in relation to the limits, the different stages of the mourning process will have to be gone through with them, for this process is at work throughout one's entire life, and particularly at turning points or times of crisis.El sufrimiento de las personas que confrontran el fin de sus vidas y el de la familia que las acompaña no está basado solamente en la visión que tengan de la muerte, difícil como es de imaginarla, sino también en el balance que hacen de su "historia de vida". Este balance se elabora según una representación compleja de la situación, (a la vez individual, familiar y social), y que es grandemente deudora de las normas, de las reglas y de las lealtades que definen la ética de la familia de quién vá a morir. Según las circunstancias y en función del modo en que, desde el principio, el paciente y sus prójimos se han organizado en relación a los límites, será necesario retomar con ellos las diferentes etapas del proceso de duelo que es parte integral de toda la vida, y más especialmente de los momentos cruciales o de crisis

Cancer et famille

(from the journal abstract) Systemic model considering families of cancer patients (as units facing the disease) and treatment teams in close interactions, where the patient is often at the crossroad of spirals of enmeshment and disengagement seems mostly appropriate to be applied in oncology. In the field, indeed, the complex healthcare network and the variety of professionals and specialists involved, and the different steps, in the diagnostic and therapeutic process, may be the source of splitting that a global approach (systemic diagnostic) is able to integrate for the most benefit of the patient and family. (PsycINFO Database Record (c) 2004 APA, all rights reserved